Safety of direct oral anticoagulants in real–world clinical practice: translating the trials to everyday clinical management

References

• Shehab A, Ahmed Elnour A, Srikanth Bhagavathula A, et al. Novel oral anticoagulants and the 73rd anniversary of historical warfarin. J Saudi Heart Assoc. 2016;28:31–45.
   PubMed Web of Science ®Google Scholar
• Castles AV, Tsay I, van Gaal W. Trends in prescription of novel oral anticoagulants (NOACs) and warfarin in Australia 2010–2015. Heart Lung Circ. 2016;25:S135.
   Google Scholar
• Loo SY, Dell’Aniello S, Huiart L, et al. Trends in the prescription of novel oral anticoagulants in UK primary care. Br J Clin Pharmacol. 2017;83:2096–2106.
   PubMed Web of Science ®Google Scholar
• Kirley K, Qato DM, Kornfield R, et al. National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes. 2012;5:615–621.
   PubMed Web of Science ®Google Scholar
• Marinigh R, Lip GYH, Fiotti N, et al. Age as a risk factor for stroke in atrial fibrillation patients: implications for thromboprophylaxis. J Am Coll Cardiol. 2010;56:827–837.
   PubMed Web of Science ®Google Scholar
• Sen S, Dahlberg KW. Physician’s fear of anticoagulant therapy in nonvalvular atrial fibrillation. Am J Med Sci. 2014;348:513–521.
   PubMed Web of Science ®Google Scholar
• Camm AJ, Fox KAA. Strengths and weaknesses of ‘real-world’ studies involving non-vitamin K antagonist oral anticoagulants. Open Heart. 2018;5:e000788.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151.
   PubMed Web of Science ®Google Scholar
• Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891.
   PubMed Web of Science ®Google Scholar
• Granger CB, Alexander JH, Jjv M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992.
   PubMed Web of Science ®Google Scholar
• Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093–2104.
   PubMed Web of Science ®Google Scholar
• Bromley A, Plitt A. A review of the role of non-vitamin K oral anticoagulants in the acute and long-term treatment of venous thromboembolism. Cardiol Ther. 2018;7:1–13.
   PubMed Web of Science ®Google Scholar
• Yoon CH, Park YK, Kim SJ, et al. Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation. Stroke. 2014;45:2983–2988.
   PubMed Web of Science ®Google Scholar
• Halvorsen S, Atar D, Yang H, et al. Efficacy and safety of apixaban compared with warfarin according to age for stroke prevention in atrial fibrillation: observations from the ARISTOTLE trial. Eur Heart J. 2014;35:1864–1872.
   PubMed Web of Science ®Google Scholar
• Karamichalakis N, Georgopoulos S, Vlachos K, et al. Efficacy and safety of novel anticoagulants in the elderly. J Geriatr Cardiol. 2016;13:718–723.
   PubMedGoogle Scholar
• Heeringa J, Dam VDK, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006;27:949–953.
   PubMed Web of Science ®Google Scholar
• Vestergaard AS, Skjøth F, Larsen TB, et al. The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: A systematic review and meta-regression analysis. PLoS One. Nagler M, ed. 2017;12: e0188482.
   PubMed Web of Science ®Google Scholar
• Schmitt L, Speckman J, Ansell J. Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range. J Thromb Thrombolysis. 2003;15:213–216.
   PubMed Web of Science ®Google Scholar
• White HD, Gruber M, Feyzi J, et al. Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control. Arch Intern Med. 2007;167:239.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Lopes RD, Hanna M, et al. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation. 2013;127:2166–2176.
   PubMed Web of Science ®Google Scholar
• Wallentin L, Yusuf S, Ezekowitz MD, et al. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010;376:975–983.
   PubMed Web of Science ®Google Scholar
• Fanaroff AC, Steffel J, Alexander JH, et al. Stroke prevention in atrial fibrillation: re-defining ‘real-world data’ within the broader data universe. Eur Heart J. 2018;39:2932–2941.
   PubMed Web of Science ®Google Scholar
• Camm AJ, Amarenco P, Haas S, et al. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. Eur Heart J. 2016;37:1145–1153.
   PubMed Web of Science ®Google Scholar
• Mazurek M, Huisman MV, Lip GYH. Registries in atrial fibrillation: from trials to real-life clinical practice. Am J Med. 2017;130:135–145.
   PubMed Web of Science ®Google Scholar
• Abraham NS, Singh S, Alexander GC, et al. Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study. BMJ. 2015;350:h1857.
   PubMed Web of Science ®Google Scholar
• Adeboyeje G, Sylwestrzak G, Barron JJ, et al. Major bleeding risk during anticoagulation with warfarin, dabigatran, apixaban, or rivaroxaban in patients with nonvalvular atrial fibrillation. J Manag Care Spec Pharm. 2017;23:968–978.
   PubMed Web of Science ®Google Scholar
• Avgil Tsadok M, Jackevicius CA, Rahme E, et al. Sex differences in dabigatran use, safety, and effectiveness in a population-based cohort of patients with atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2015;8:593–599.
   PubMed Web of Science ®Google Scholar
• Avgil-Tsadok M, Jackevicius C, Essebag V, et al. Dabigatran use in elderly patients with atrial fibrillation. Thromb Haemost. 2016;115:152–160.
   PubMed Web of Science ®Google Scholar
• Bengtson LGS, Lutsey PL, Chen LY, et al. Comparative effectiveness of dabigatran and rivaroxaban versus warfarin for the treatment of non-valvular atrial fibrillation. J Cardiol. 2017;69:868–876.
   PubMed Web of Science ®Google Scholar
• Cha M-J, Choi E-K, Han K-D, et al. Effectiveness and safety of non-vitamin K antagonist oral anticoagulants in Asian patients with atrial fibrillation. Stroke. 2017;48:3040–3048.
   PubMed Web of Science ®Google Scholar
• Chang H-Y, Zhou M, Tang W, et al. Risk of gastrointestinal bleeding associated with oral anticoagulants: population based retrospective cohort study. BMJ. 2015;350:h1585.
   PubMed Web of Science ®Google Scholar
• Graham DJ, Reichman ME, Wernecke M, et al. Cardiovascular, bleeding, and mortality risks in elderly medicare patients treated with dabigatran or warfarin for nonvalvular atrial fibrillation. Circulation. 2015;131:157–164.
   PubMed Web of Science ®Google Scholar
• Hernandez I, Baik SH, Piñera A, et al. Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med. 2015;175:18.
   PubMed Web of Science ®Google Scholar
• Kohsaka S, Murata T, Izumi N, et al. Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data. Curr Med Res Opin. 2017;33:1955–1963.
   PubMed Web of Science ®Google Scholar
• Larsen TB, Skjøth F, Nielsen PB, et al. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2016;353:i3189.
   PubMed Web of Science ®Google Scholar
• Larsen TB, Gorst-Rasmussen A, Rasmussen LH, et al. Bleeding events among new starters and switchers to dabigatran compared with warfarin in atrial fibrillation. Am J Med. 2014;127:650–656.e5.
   PubMed Web of Science ®Google Scholar
• Lauffenburger JC, Farley JF, Gehi AK, et al. Safety of dabigatran and warfarin in real‐world US patients with non‐valvular atrial fibrillation: a retrospective cohort study. J Am Heart Assoc. 2015;4:e001798-e001798. doi:10.1161/JAHA.115.001798.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Pan X, Kamble S, et al. Major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real-world” observational study in the United States. Int J Clin Pract. 2016;70:752–763.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Keshishian A, Kamble S, et al. Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. Thromb Haemost. 2016;116:975–986.
   PubMed Web of Science ®Google Scholar
• Nishtala PS, Gnjidic D, Jamieson HA, et al. ‘Real-world’ haemorrhagic rates for warfarin and dabigatran using population-level data in New Zealand. Int J Cardiol. 2016;203:746–752.
   PubMed Web of Science ®Google Scholar
• Palamaner Subash Shantha G, Pd B, Girotra S, et al. Sex-specific comparative effectiveness of oral anticoagulants in elderly patients with newly diagnosed atrial fibrillation. Circ Cardiovasc Qual Outcomes. 2017;10.
   PubMed Web of Science ®Google Scholar
• Tepper PG, Mardekian J, Masseria C, et al. Real-world comparison of bleeding risks among non-valvular atrial fibrillation patients prescribed apixaban, dabigatran, or rivaroxaban. PLoS One. Garcia de Frutos P, ed. 2018;13:e0205989.
   PubMed Web of Science ®Google Scholar
• Villines TC, Schnee J, Fraeman K, et al. A comparison of the safety and effectiveness of dabigatran and warfarin in non-valvular atrial fibrillation patients in a large healthcare system. Thromb Haemost. 2015;114:1290–1298.
   PubMed Web of Science ®Google Scholar
• Yao X, Abraham NS, Sangaralingham LR, et al. Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart Assoc. 2016;5:e003725. doi:10.1161/JAHA.116.003725
   Web of Science ®Google Scholar
• Yap LB, Eng DTS, Sivalingam L, et al. A comparison of dabigatran with warfarin for stroke prevention in atrial fibrillation in an Asian population. Clin Appl Thromb. 2016;22:792–797.
   PubMed Web of Science ®Google Scholar
• Coleman CI, Turpie AGG, Bunz TJ, et al. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1. Eur Heart J Cardiovasc Pharmacother. 2018 July.
   PubMedGoogle Scholar
• Coleman CI, Antz M, Bowrin K, et al. Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study. Curr Med Res Opin. 2016;32:2047–2053.
   PubMed Web of Science ®Google Scholar
• Halvorsen S, Ghanima W, Fride Tvete I, et al. A nationwide registry study to compare bleeding rates in patients with atrial fibrillation being prescribed oral anticoagulants. Eur Heart J Cardiovasc Pharmacother. 2017;3:28–36.
   PubMed Web of Science ®Google Scholar
• Laliberté F, Cloutier M, Nelson WW, et al. Real-world comparative effectiveness and safety of rivaroxaban and warfarin in nonvalvular atrial fibrillation patients. Curr Med Res Opin. 2014;30:1317–1325.
   PubMed Web of Science ®Google Scholar
• Lamberts M, Staerk L, Olesen JB, et al. Major bleeding complications and persistence with oral anticoagulation in non‐valvular atrial fibrillation: contemporary findings in real‐life Danish patients. J Am Heart Assoc. 2017;6:e004517. doi: 10.1161/JAHA.116.004517
   PubMed Web of Science ®Google Scholar
• Norby FL, Bengtson LGS, Lutsey PL, et al. Comparative effectiveness of rivaroxaban versus warfarin or dabigatran for the treatment of patients with non-valvular atrial fibrillation. BMC Cardiovasc Disord. 2017;17:238.
   PubMed Web of Science ®Google Scholar
• Russo-Alvarez G, Martinez KA, Valente M, et al. Thromboembolic and major bleeding events with rivaroxaban versus warfarin use in a real-world setting. Ann Pharmacother. 2018;52:19–25.
   PubMed Web of Science ®Google Scholar
• Coleman CI, Antz M. Real-world evidence with apixaban for stroke prevention in patients with nonvalvular atrial fibrillation in Germany: a retrospective study (REASSESS). Intern Emerg Med. 2017;12:419–422.
   PubMed Web of Science ®Google Scholar
• Li X, Keshishian A, Hamilton M, et al. Apixaban 5 and 2.5 mg twice-daily versus warfarin for stroke prevention in nonvalvular atrial fibrillation patients: comparative effectiveness and safety evaluated using a propensity-score-matched approach. PLoS One. Garcia de Frutos P, ed. 2018;13:e0191722.
   PubMed Web of Science ®Google Scholar
• Li X, Deitelzweig S, Keshishian A, et al. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice. Thromb Haemost. 2017;117:1072–1082.
   PubMed Web of Science ®Google Scholar
• Ramagopalan S, Allan V, Saragoni S, et al. Patient characteristics and bleeding events in nonvalvular atrial fibrillation patients treated with apixaban or vitamin K antagonists: real-world evidence from Italian administrative databases. J Comp Eff Res. 2018;7:1063–1071.
   PubMed Web of Science ®Google Scholar
• Abraham NS, Noseworthy PA, Yao X, et al. Gastrointestinal safety of direct oral anticoagulants: a large population-based study. Gastroenterology. 2017;152:1014–1022.e1.
   PubMed Web of Science ®Google Scholar
• Gupta K, Trocio J, Keshishian A, et al. Real-world comparative effectiveness, safety, and health care costs of oral anticoagulants in nonvalvular atrial fibrillation patients in the U.S. department of defense population. J Manag Care Spec Pharm. 2018;24:1116–1127.
   PubMed Web of Science ®Google Scholar
• Lin J, Trocio J, Gupta K, et al. Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting. J Med Econ. 2017;20:952–961.
   PubMed Web of Science ®Google Scholar
• Potpara TS, Polovina MM, Licina MM, et al. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban. Adv Ther. 2012;29:491–507.
   PubMed Web of Science ®Google Scholar
• Wells G, Coyle D, Cameron C, et al. Safety, effectiveness, and cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Ottowa: Canadian Agency for Drugs and Technologies in Health Therapeutic Reviews; 2012.
   Google Scholar
• Hohnloser SH, Oldgren J, Yang S, et al. Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (randomized evaluation of long-term anticoagulation therapy) Trial. 2012.
   Google Scholar
• Uchino K, Hernandez AV. Dabigatran association with higher risk of acute coronary events. Arch Intern Med. 2012;172:397.
   PubMed Web of Science ®Google Scholar
• Artang R, Rome E, Nielsen JD, et al. Meta-analysis of randomized controlled trials on risk of myocardial infarction from the use of oral direct thrombin inhibitors. Am J Cardiol. 2013;112:1973–1979.
   PubMed Web of Science ®Google Scholar
• Larsen TB, Rasmussen LH, Gorst-Rasmussen A, et al. Myocardial ischemic events in ‘real world’ patients with atrial fibrillation treated with dabigatran or warfarin. Am J Med. 2014;127:329–336.e4.
   PubMed Web of Science ®Google Scholar
• Ntaios G, Papavasileiou V, Makaritsis K, et al. Real-world setting comparison of nonvitamin-K antagonist oral anticoagulants versus vitamin-K antagonists for stroke prevention in atrial fibrillation. Stroke. 2017;48:2494–2503.
   PubMed Web of Science ®Google Scholar
• Lee CJ-Y, Gerds TA, Carlson N, et al. Risk of myocardial infarction in anticoagulated patients with atrial fibrillation. J Am Coll Cardiol. 2018;72:17–26.
   PubMed Web of Science ®Google Scholar
• Nielsen PB, Skjøth F, Søgaard M, et al. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ. 2017;356:j510.
   PubMed Web of Science ®Google Scholar
• Gorst-Rasmussen A, Lip GYH, Bjerregaard Larsen T. Rivaroxaban versus warfarin and dabigatran in atrial fibrillation: comparative effectiveness and safety in Danish routine care. Pharmacoepidemiol Drug Saf. 2016;25:1236–1244.
   PubMed Web of Science ®Google Scholar
• Chan Y, See L, Tu H, et al. Efficacy and safety of apixaban, dabigatran, rivaroxaban, and warfarin in Asians with nonvalvular atrial fibrillation. J Am Heart Assoc. 2018;7:e008150. doi:10.1161/JAHA.117.008150.
   Web of Science ®Google Scholar
• Deitelzweig S, Luo X, Gupta K, et al. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients. Curr Med Res Opin. 2017;33:1745–1754.
   PubMed Web of Science ®Google Scholar
• Lip GYH, Keshishian A, Li X, et al. Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients: the ARISTOPHANES study. Am Heart Assoc J. 2018;49:2933–2944.
   Google Scholar
• Hernandez I, Zhang Y. Comparing stroke and bleeding with rivaroxaban and dabigatran in atrial fibrillation: analysis of the US medicare part D data. Am J Cardiovasc Drugs. 2017;17:37–47.
   PubMed Web of Science ®Google Scholar
• Noseworthy PA, Yao X, Abraham NS, et al. Direct comparison of dabigatran, rivaroxaban, and apixaban for effectiveness and safety in nonvalvular atrial fibrillation. Chest. 2016;150:1302–1312.
   PubMed Web of Science ®Google Scholar
• Graham DJ, Reichman ME, Wernecke M, et al. Stroke, bleeding, and mortality risks in elderly medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation. JAMA Intern Med. 2016;176:1662.
   PubMed Web of Science ®Google Scholar
• Bai Y, Deng H, Shantsila A, et al. Rivaroxaban versus dabigatran or warfarin in real-world studies of stroke prevention in atrial fibrillation. Stroke. 2017;48:970–976.
   PubMed Web of Science ®Google Scholar
• Goodman SG, Wojdyla DM, Piccini JP, et al. Factors associated with major bleeding events: insights from the ROCKET AF trial (rivaroxaban once-daily oral direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation). J Am Coll Cardiol. 2014;63:891–900.
   PubMed Web of Science ®Google Scholar
• DeWald TA, Becker RC. The pharmacology of novel oral anticoagulants. J Thromb Thrombolysis. 2014;37:217–233.
   PubMed Web of Science ®Google Scholar
• ERIKSSON BI, Borris L, Oe DAHL, et al. Oral, direct Factor Xa inhibition with BAY 59-7939 for the prevention of venous thromboembolism after total hip replacement. J Thromb Haemost. 2006;4:121–128.
   PubMed Web of Science ®Google Scholar
• Eriksson BI, Borris LC, Dahl OE, et al. A once-daily, oral, direct factor Xa inhibitor, RIVAROXABAN (BAY 59-7939), for thromboprophylaxis after total hip replacement. Circulation. 2006;114:2374–2381.
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Eikelboom J, Joyner C, et al. Apixaban in patients with atrial fibrillation. N Engl J Med. 2011;364:806–817.
   PubMed Web of Science ®Google Scholar
• Proietti M, Romanazzi I, Romiti GF, et al. Real-world use of apixaban for stroke prevention in atrial fibrillation. Stroke. 2018;49:98–106.
   PubMed Web of Science ®Google Scholar
• Lee S-R, Choi E-K, Han K-D, et al. Edoxaban in asian patients with atrial fibrillation. J Am Coll Cardiol. 2018;72:838–853.
   PubMedGoogle Scholar
• Kato ET, Giugliano RP, Ruff CT, et al. Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF–TIMI 48 trial. J Am Heart Assoc. 2016;5:e003432. doi:10.1161/JAHA.116.003432.
   Web of Science ®Google Scholar
• Reilly PA, Lehr T, Haertter S, et al. The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients. J Am Coll Cardiol. 2014;63:321–328.
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Wallentin L, Connolly SJ, et al. Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation. Circulation. 2011;123:2363–2372.
   PubMed Web of Science ®Google Scholar
• Alnsasra H, Haim M, Senderey AB, et al. Net clinical benefit of oral anticoagulant treatments in elderly patients with non-valvular atrial fibrillation. experience from the real world. HeartRhythm. 2018;16(1):31–37.
   Google Scholar
• Chao T-F, Liu C-J, Lin Y-J, et al. Oral anticoagulation in very elderly patients with atrial fibrillation. Circulation. 2018;138:37–47.
   PubMed Web of Science ®Google Scholar
• Chan P-H, Huang D, Hai JJ, et al. Stroke prevention using dabigatran in elderly Chinese patients with atrial fibrillation. Hear Rhythm. 2016;13:366–373.
   PubMed Web of Science ®Google Scholar
• Steffel J, Verhamme P, Potpara TS, et al. The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J. 2018;21;39(16):1330–1393.
   Google Scholar
• Ageno W, Gallus MBBS AS, Wittkowsky PharmD A, et al. Oral anticoagulant therapy: antithrombotic Therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141:e44S–e88S.
   PubMed Web of Science ®Google Scholar
• Ho P, Brooy B, Hayes L, et al. Direct oral anticoagulants in frail older adults: a geriatric perspective. Semin Thromb Hemost. 2015;41:389–394.
   PubMed Web of Science ®Google Scholar
• Fawzy AM, Olshansky B, Lip GYH. Frailty and multi-morbidities should not govern oral anticoagulation therapy prescribing for patients with atrial fibrillation. Am Heart J. 2018 October.
   PubMed Web of Science ®Google Scholar
• Lutz J, Jurk K, Schinzel H. Direct oral anticoagulants in patients with chronic kidney disease: patient selection and special considerations. Int J Nephrol Renovasc Dis. 2017;10:135–143.
   PubMed Web of Science ®Google Scholar
• Hijazi Z, Hohnloser SH, Oldgren J, et al. Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation. Circulation. 2014;129:961–970.
   PubMed Web of Science ®Google Scholar
• Mao L, Li C, Li T, et al. Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in Chinese patients with atrial fibrillation. Vascular. 2014;22:252–258.
   PubMed Web of Science ®Google Scholar
• Hohnloser SH, Hijazi Z, Thomas L, et al. Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation: insights from the ARISTOTLE trial. Eur Heart J. 2012;33:2821–2830.
   PubMed Web of Science ®Google Scholar
• Bohula EA, Giugliano RP, Ruff CT, et al. Impact of renal function on outcomes with edoxaban in the ENGAGE AF-TIMI 48 Trial. Circulation. 2016;134:24–36.
   PubMed Web of Science ®Google Scholar
• Ciurus T, Sobczak S, Cichocka-Radwan A, et al. New oral anticoagulants - a practical guide. Kardiochirurgia I Torakochirurgia Pol = Polish J Cardio-Thoracic Surg. 2015;12:111–118.
   PubMed Web of Science ®Google Scholar
• Kubisz P, Stanciakova L, Dobrotova M, et al. Apixaban - metabolism, pharmacologic properties and drug interactions. Curr Drug Metab. 2017;18:609–621.
   PubMed Web of Science ®Google Scholar
• Loo SY, Coulombe J, Dell’Aniello S, et al. Comparative effectiveness of novel oral anticoagulants in UK patients with non-valvular atrial fibrillation and chronic kidney disease: A matched cohort study. BMJ Open. 2018;8:e019638.
   PubMed Web of Science ®Google Scholar
• Yu HT, Yang P-S, Kim T-H, et al. Impact of renal function on outcomes with edoxaban in real-world patients with atrial fibrillation. Stroke. 2018;49:2421–2429.
   PubMed Web of Science ®Google Scholar
• Weir, M; Haskell LB, Berger JS et al. Evaluation of clinical outcomes among nonvalvular atrial fibrillation patients treated with rivaroxaban or warfarin, stratified by renal function. Clin Nephrol. 2018;89:314–329.
   PubMed Web of Science ®Google Scholar
• Abdou JK, Auyeung V, Patel JP, et al. Adherence to long-term anticoagulation treatment, what is known and what the future might hold. Br J Haematol. 2016;174:30–42.
   PubMed Web of Science ®Google Scholar
• Garkina SV, Vavilova TV, Lebedev DS, et al. Compliance and adherence to oral anticoagulation therapy in elderly patients with atrial fibrillation in the era of direct oral anticoagulants. J Geriatr Cardiol. 2016;13:807–810.
   PubMedGoogle Scholar
• Almegren M. Reversal of direct oral anticoagulants. Vasc Health Risk Manag. 2017;13:287–292.
   PubMed Web of Science ®Google Scholar
• Pollack CV, Reilly PA, Eikelboom J, et al. Idarucizumab for dabigatran reversal. N Engl J Med. 2015;373:511–520.
   PubMed Web of Science ®Google Scholar
• Heo Y-A. Andexanet alfa: first global approval. Drugs. 2018;78:1049–1055.
   PubMed Web of Science ®Google Scholar
• Gadsbøll K, Staerk L, Fosbøl EL, et al. Increased use of oral anticoagulants in patients with atrial fibrillation: temporal trends from 2005 to 2015 in Denmark. Eur Heart J. 2017;38:ehw658.
   Google Scholar
• Heidbuchel H, Verhamme P, Alings M, et al. Updated European heart rhythm association practical guide on the use of non-vitamin K antagonist anticoagulants in patients with non-valvular atrial fibrillation. Europace. 2015;17:1467–1507.
   PubMed Web of Science ®Google Scholar
• Kirchhof P, Benussi S, Kotecha D, et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardio Thoracic Surg. 2016;50:e1–e88.
   PubMed Web of Science ®Google Scholar
• Mackman N. The role of tissue factor and factor VIIa in hemostasis. Anesth Analg. 2009;108:1447–1452.
   PubMed Web of Science ®Google Scholar
• Harter K, Levine M, Henderson SO. Anticoagulation drug therapy: a review. West J Emerg Med. 2015;16:11–17.
   PubMed Web of Science ®Google Scholar
• Goriacko P, Yaghdjian V, Koleilat I, et al. The use of idarucizumab for dabigatran reversal in clinical practice: a case series. P T. 2017;42:699–703.
   PubMedGoogle Scholar
• Vosko MR, Bocksrucker C, Drwiła R, et al. Real-life experience with the specific reversal agent idarucizumab for the management of emergency situations in dabigatran-treated patients: a series of 11 cases. J Thromb Thrombolysis. 2017;43:306–317.
   PubMed Web of Science ®Google Scholar
• Burnett A, Siegal D, Crowther M. Specific antidotes for bleeding associated with direct oral anticoagulants. BMJ. 2017;357:j2216.
   PubMedGoogle Scholar
• Reinecke H, Jürgensmeyer S, Engelbertz C, et al. Design and rationale of a randomised controlled trial comparing apixaban to phenprocoumon in patients with atrial fibrillation on chronic haemodialysis: the AXADIA-AFNET 8 study. BMJ Open. 2018;8:e022690.
   PubMed Web of Science ®Google Scholar